Savara/$SVRA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Savara
Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system.
Ticker
$SVRA
Sector
Primary listing
Employees
59
Headquarters
Website
Savara Metrics
BasicAdvanced
$643M
-
-$0.51
0.40
-
Price and volume
Market cap
$643M
Beta
0.4
52-week high
$4.54
52-week low
$1.89
Average daily volume
1.1M
Financial strength
Current ratio
11.079
Quick ratio
10.859
Long term debt to equity
24.612
Total debt to equity
24.686
Profitability
EBITDA (TTM)
-116.493
Management effectiveness
Return on assets (TTM)
-48.04%
Return on equity (TTM)
-99.30%
Valuation
Price to book
5.33
Price to tangible book (TTM)
5.9
Price to free cash flow (TTM)
-6.598
Free cash flow yield (TTM)
-15.16%
Free cash flow per share (TTM)
-0.462
Growth
Earnings per share change (TTM)
22.73%
3-year earnings per share growth (CAGR)
25.87%
What the Analysts think about Savara
Analyst ratings (Buy, Hold, Sell) for Savara stock.
Savara Financial Performance
Revenues and expenses
Savara Earnings Performance
Company profitability
Savara News
AllArticlesVideos
New England Journal of Medicine (NEJM) to Publish Results From Savara's Pivotal Phase 3 IMPALA-2 Clinical Trial in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)
Business Wire·2 days ago
Savara to Present New Data from the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the European Respiratory Society Congress 2025
Business Wire·4 days ago
Savara Reports Second Quarter 2025 Financial Results and Provides a Business Update
Business Wire·1 week ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Savara stock?
Savara (SVRA) has a market cap of $643M as of August 22, 2025.
What is the P/E ratio for Savara stock?
The price to earnings (P/E) ratio for Savara (SVRA) stock is 0 as of August 22, 2025.
Does Savara stock pay dividends?
No, Savara (SVRA) stock does not pay dividends to its shareholders as of August 22, 2025.
When is the next Savara dividend payment date?
Savara (SVRA) stock does not pay dividends to its shareholders.
What is the beta indicator for Savara?
Savara (SVRA) has a beta rating of 0.4. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.